Krajina: Austrália
Jazyk: angličtina
Zdroj: Department of Health (Therapeutic Goods Administration)
potassium clavulanate, Quantity: 149.774 mg (Equivalent: clavulanic acid, Qty 125 mg); amoxicillin trihydrate, Quantity: 1012.617 mg (Equivalent: amoxicillin, Qty 875 mg)
Pharmacor Pty Ltd
amoxicillin trihydrate,potassium clavulanate
Tablet, film coated
Excipient Ingredients: colloidal anhydrous silica; sodium starch glycollate type A; isopropyl alcohol; magnesium stearate; dichloromethane; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose
Oral
10 tablets
(S4) Prescription Only Medicine
CLAVAMOX Tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to Microbiology):,Urinary Tract Infections (uncomplicated and complicated), Lower Respiratory Tract Infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, Upper Respiratory Tract Infections, such as sinusitis, otitis media and recurrent tonsillitis.Skin and Skin Structure Infection.,Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to CLAVAMOX Tablets. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate.,The treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to CLAVAMOX Tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.
Visual Identification: White to off white capsule shaped, biconvex, film coated tablets debossed with AM and CL separated by break line on one side and 1000 on other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2013-11-14
CLAVAMOX Ver: 03 1 CLAVAMOX (Amoxicillin & Clavulanic Acid) CONSUMER MEDICINE INFORMATION (CMI) WHAT IS IN THIS LEAFLET? Please read this leaflet carefully before you take CLAVAMOX tablets. This leaflet answers some common questions about CLAVAMOX tablets. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Sometimes ne risks are found even when a medicine has been used for many years. Your doctor has weighed the expected benefits of you taking CLAVAMOX tablets against the risks this medicine could have for you. If you have any concerns about taking this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. WHAT ARE CLAVAMOX TABLETS USED FOR? CLAVAMOX tablets contain two active ingredients. One of these is a penicillin called amoxycillin and the other is clavulanic acid. CLAVAMOX tablets belong to the penicillin group of antibiotics. CLAVAMOX tablets are used for the short term treatment of wide range of infections caused by bacteria. These infections may affect the chest (e.g. bronchitis or pneumonia), bladder (e.g. cystitis), sinuses (e.g. sinusitis), the ears (e.g. otitis media) or the skin. CLAVAMOX tablets work by killing the bacteria that cause these infections. CLAVAMOX tablets will not work against infections caused by viruses such as colds or the flu. Your doctor may have prescribed it for another reason. If you want more information ask your doctor. This medicine is available only with a doctor’s prescription. There is no evidence that it is addictive. BEFORE YOU TAKE CLAVAMOX TABLETS _DO NOT TAKE CLAVAMOX _ _TABLETS IF:_ you have had an allergic reaction to penicillin or similar types of antibiotics (such as cephalosporins) or any of the ingredients contained in CLAVAMOX tablets. _The ingredients are _ _listed _ _at _ _the_ _end _ _of _ _this _ _leaflet. _ _Some _ _of _ _the _ _symptoms _ _of _ _an _ _allergic _ _reaction _ _may _ _inc Prečítajte si celý dokument
CLAVAMOX Ver-04 1 AUSTRALIAN PRODUCT INFORMATION - CLAVAMOX 875MG/125MG TABLETS (AMOXICILLIN AND POTASSIUM CLAVULANATE TABLETS) 1. NAME OF THE MEDICINE Amoxicillin trihydrate and Potassium clavulanate. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CLAVAMOX 875MG/125MG TABLETS is a combination product containing the semisynthetic antibiotic, amoxicillin (as the trihydrate) and the β-lactamase inhibitor, potassium clavulanate (as the potassium salt of clavulanic acid). For full list of excipients, see SECTION 6.1- LIST OF EXCIPIENTS 3. PHARMACEUTICAL FORM CLAVAMOX 875 MG/125 MG TABLETS: White to off white capsule shaped, biconvex, film coated tablets debossed with AM and CL separated by breakline on one side and 1000 on other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS CLAVAMOX 875 mg/125 mg tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (see SECTION 5.1 PHARMACODYNAMIC PROPERTIES, MICROBIOLOGY ): Urinary Tract Infections (uncomplicated and complicated) Lower Respiratory Tract Infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis Upper Respiratory Tract Infections, such as sinusitis, otitis media and recurrent tonsillitis. Skin and Skin Structure Infection. Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and potassium clavulanate CLAVAMOX Ver-04 2 tablets. However, when there is reason to believe an infection may involve any of the β- lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. The treatment of mixed infections caused by amoxicillin susceptible organisms and β-lactamase producing organisms susceptible to amoxicillin and potassium clavulanate tablets should not require the addition of another Prečítajte si celý dokument